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Signals that promotemyelinationmust be tightlymodulated to adjustmyelin thickness to the axonal diameter. In the peripheral nervous
system, axonal neuregulin 1 type III promotes myelination by activating erbB2/B3 receptors and the PI3K/AKT/mTOR pathway in
Schwann cells. Conversely, PTEN (phosphatase and tensin homolog on chromosome 10) dephosphorylates PtdIns(3,4,5)P3 and nega-
tively regulates the AKTpathway andmyelination. Recently, the DLG1/SAP97 scaffolding proteinwas described to interact with PTEN to
enhance PIP3 dephosphorylation. Here we now report that nerves from mice with conditional inactivation of Dlg1 in Schwann cells
display only a transient increase in myelin thickness during development, suggesting that DLG1 is a transient negative regulator of
myelination. Instead, we identified DDIT4/RTP801/REDD1 as a sustained negative modulator of myelination. We show that DDIT4 is
expressed in Schwann cells and its maximum expression level precedes the peak of AKT activation and of DLG1 activity in peripheral
nerves. Moreover, loss of DDIT4 expression both in vitro and in vivo in Ddit4-null mice provokes sustained hypermyelination and
enhanced mTORC1 activation, thus suggesting that this molecule is a novel negative regulator of PNSmyelination.
Introduction
Myelin, a highly specialized spiral membrane, ensures proper
transmission of electric impulses, regulates axonal physiology,
and determines the molecular domain organization of axons.
Myelin-forming cells are Schwann cells in the peripheral nervous
system (PNS) and oligodendrocytes in the CNS (Nave, 2010).
In the PNS, axonal neuregulin (NRG) 1 type III is one of the
main signals that promotes myelination and remyelination after
injury (Nave and Salzer, 2006). NRG1 type III binds to erbB2/B3
receptors in Schwann cells and transduces the signal through the
PI3K/AKT (phosphatidylinositol 3-kinase/v-AKT murine thy-
moma viral oncogene homolog) pathway (Pereira et al., 2012).
PI3K class I generates PtdIns(3,4,5)P3 (PIP3) at the plasmamem-
brane and contributes to AKT/mTOR (the mammalian target of
rapamycin kinase) activation (Harrington et al., 2005; Sarbassov
et al., 2005; Guertin and Sabatini, 2007; Polak and Hall, 2009).
Consistent with this, overexpression of NRG1 type III causes
hypermyelination with increased myelin thickness (Michailov
et al., 2004). The opposite phenotype, hypomyelination with
reduced myelin thickness, has been observed in Nrg1/ and
Nrg1///erbB2/ double-heterozygous mice and, more re-
cently, in mice with Schwann cell-conditional inactivation of
mTOR (Michailov et al., 2004; Taveggia et al., 2005; Sherman
et al., 2012). Proper control of myelination is fundamental, as
either reduced myelination (hypo/demyelination) or focal ex-
cessive myelination (hypermyelination) is associated with pe-
ripheral neuropathies (Pareyson and Marchesi, 2009).
During development, the PI3K/AKT pathway must be nega-
tively modulated to adjust myelin thickness to axonal diameter.
Indeed, PI3K/AKT activation is attenuated by the PTEN (phos-
phatase and tensin homolog on chromosome 10) phosphatase,
which dephosphorylates PIP3 in the three position, thus produc-
ing PtdIns(4,5)P2. Accordingly, conditional inactivation of Pten
in either Schwann cells or oligodendrocytes in vivo provokes sus-
tained hypermyelination (Goebbels et al., 2010, 2012;Harrington
et al., 2010). More recently, the DLG1 scaffolding protein was
suggested as the main brake of PNS myelination (Cotter et al.,
2010; Macklin, 2010; Roberts and Lloyd, 2012). DLG1 is believed
to potentiate PTEN activity toward PIP3, thus negatively modu-
lating the AKT-mTOR pathway. Indeed, acute postnatal down-
regulation of Dlg1 expression in the nerve by means of lentiviral
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vector (LV) transduction leads to hypermyelination and ulti-
mately to myelin instability (Cotter et al., 2010).
Here we report that nerves from mice with conditional inac-
tivation ofDlg1 in Schwann cells display only a transient increase
in myelin thickness during development. Further, we identified
DDIT4/RTP801/REDD1 as a novel negative modulator of myeli-
nation. In both Drosophila and mammalian cells, DDIT4 is
known to negatively modulate the mTOR pathway by activat-
ing the tuberous sclerosis complex TSC1/2, which are GAPs
for the Rheb1 GTPase (Abraham, 2005; Ellisen, 2005; Maiese
et al., 2013). TSC1/2 regulation of mTORC1 activity involves
phosphorylation-dependent association of TSC2 with 14-3-3
proteins and this interaction has been shown to inhibit
TSC1/2 signaling to mTORC1 (mTORC1 is active). DDIT4
interacts with 14-3-3 proteins, thus inducing 14-3-3 dissocia-
tion from TSC2, activation of TSC1/2 GAPs, and inhibition of
mTORC1 (DeYoung et al., 2008).
Here we report that DDIT4 upregulation in the nerve compen-
sates for the loss of AKT/mTOR inhibition in Dlg1-null mice,
whereas its loss both in vitro and in vivo in Ddit4-null mice persis-
tently activates the mTOR pathway and causes hypermyelination.
Materials andMethods
Mice and genotyping.The generation of theDlg1 floxed (fl, C57/B6 strain)
allele used in this study has been already reported (Zhou et al., 2008). To
produce conditional knockout mice with ablation of Dlg1 specifically in
Schwann cells (Dlg1 fl/fl P0Cre), homozygous Dlg1 fl/fl mice were crossed
with heterozygous Dlg1 fl/mice carrying the P0Cre transgene (Feltri et
al., 1999). To obtain Dlg1 fl/ P0Cre conditional knockout mice (com-
pound heterozygous for a floxed allele and a null allele), Dlg1 fl/ mice
were crossed with CMVCre transgenic mice and the resulting Dlg1/
mice were then crossed with Dlg1 fl/ P0Cre animals.
Ddit4-nullmice (C57/B6 strain)were already reported (Brafman et al.,
2004). The characterization of vimentin (Vim)-null mice was also re-
cently reported (Triolo et al., 2012). For all the experiments involving
animals, n3 animals per genotype of either sex were analyzed. Floxed/
floxed or floxed/ or/mice were independently used as controls, as
littermates of knockout mice analyzed within the same experiments [in-
dicated as “wild type” (WT) for clarity in figures].
All experiments involving animals were performed in accordance with
Italian national regulations and covered by experimental protocols re-
viewed by local institutional animal care and use committees.
Antibodies. ForWestern blot analysis and immunohistochemistry, the
following antibodies were used: mouse anti-DLG1 (Enzo Life Sciences),
rabbit anti-PTEN (Cell Signaling Technology), rabbit anti-phospho-
AKT (Ser473 and Thr308; Cell Signaling Technology), rabbit anti-AKT
(pan; Cell Signaling Technology), rabbit anti-calnexin (Sigma-Aldrich),
chicken anti-P0 (Millipore), mouse anti-tubulin (Sigma-Aldrich), rabbit
anti-Krox20 (Covance), rabbit anti-PS6 (Cell Signaling Technology), hy-
bridoma rat anti-MBP (kindly provided by Dr V. Lee), rabbit anti-heavy
neurofilament (Millipore), rabbit anti-light neurofilament (NF-L; Co-
vance), goat anti-REDD1 (Yoshida et al., 2010), rabbit anti-REDD1
(Epitomics), goat anti-HIF3 (Santa Cruz Biotechnology).
Secondary antibodies included peroxidase-conjugated goat anti-mouse,
anti-rabbit, or anti-chicken IgG (Dako); IRDye680 and800-conjugated goat
anti-mouse and/or goat anti-rabbit IgG (Li-Cor Biosciences); fluorescein
(FITC)-conjugated goat anti-rabbit IgG; and rhodamine (TRITC)-
conjugated anti-rat IgG (Jackson Immunoresearch).
Protein lysates fromDRGexplants and purified rat Schwann cells were
prepared using a lysis buffer containing the following: 1%TX-100, 50mM
Tris buffer, pH 8.0, 150 mM NaCl, 10 mM NaF, 1 mM Na vanadate,
Complete (Roche) protease inhibitors. For mouse nerve lysates, a lysis
buffer containing 2% SDS was used.
Schwann cell/DRG neuron cocultures. Myelin-forming Schwann cell/
DRG neuron cocultures were established from embryonic day (E) 13.5
mouse embryos as previously described (Bolis et al., 2009). Briefly, DRGs
were plated (1:1 ratio) on 12-mm-diameter glass coverslips (Greiner)
coated with rat collagen (0.2 mg/ml; Becton Dickinson) in C media,
consisting of Eagle’s Minimal Essential Medium (Invitrogen) supple-
mented with 10% fetal calf serum (FCS; Invitrogen), 5 mg/ml glucose
(Sigma-Aldrich), 50 g/ml 2.5S nerve growth factor (NGF; Harlan or
Calbiochem). DRGs were then placed in neurobasal medium (NB; Invit-
rogen) supplemented with B27 (Invitrogen) and NGF as before until
neuritogenesis was achieved. For myelination, DRGs were placed on
C media supplemented with ascorbic acid for 7–15 d (50 g/ml;
Sigma-Aldrich).
Isolated rat Schwann cells were prepared as reported previously and
cultured using DMEM with 10% FCS, 2 ng/ml recombinant human
neuregulin1-b1 (R&D Systems), and 2 mM forskolin (Calbiochem). To
stimulate rat Schwann cells with NRG1, subconfluent cells were starved
for 16 h in DMEM containing only 0.05% serum and then treated for 15
min with complete medium containing neuregulin and serum.
Immunohistochemistry. Schwann cell/DRG neuron cocultures were
fixed for 15 min in 4% paraformaldehyde, permeabilized for 5 min in
ice-coldmethanol at20°C, blocked for 20minwith 10%NGS, 1%BSA,
and then incubated with primary antibody for 1 h. After washing, the
coverslips were incubated with the secondary antibody for 30 min,
washed, and mounted. For double immunostaining with anti-NF-L and
anti-MBP antibody, the coverslips were blocked with 1%BSA, 10%NGS
for 20 min and primary antibodies were incubated overnight at 4°C.
Analysis of myelination. To quantify the amount of myelin,5 fields/
cover were randomly acquired using a fluorescence microscope near the
sensory neurons, where usually myelination is more efficient and abun-
dant and MBP-positive myelinated fibers were counted per field. As
myelination is also a function of the amount of neurites per axon and of
the Schwann cell number in the culture, the network of NF-L-positive
segments and the number of Schwann cells (DAPI)were also evaluated in
each explant. Representative images of MBP-NF-DAPI staining have
been acquired using a confocal microscope (Leica SP5).
Lentivirus preparation and infection. To downregulate Ddit4 expres-
sion in vitro, nonconcentrated LVs carrying shRNA for Ddit4 (GFP-tag)
were used to transduce isolated rat Schwann cells and mouse explants
(clone ID V3LMM 468446, pGIPZ vector, shRNA mir; Thermo Scien-
tific). To produce nonconcentrated LVs, the transfer constructs were
transfected into 293FT cells together with packaging plasmids 8.9 and
pCMV-VSGV using Lipofectamine 2000 (Invitrogen). As control, a vec-
tor encoding a shRNA targeting a nonspecific sequence (luciferase) was
used. Viral supernatants were collected after 72 h after transfection, cen-
trifuged at 3,000 rpm for 15 min, and frozen at80°C.
To check for DDIT4 depletion, freshly plated rat Schwann cells (106
cells per 100 mm plate) were incubated with the LVs for two consecutive
overnights in DMEM, 10% FBS, and 2 mM L-glutamine plus forskolin
and rhNRG-1 (EGF domain; R&D Systems). Cells were expanded for an
additional week and maintained in MEM, 10% FBS, 2 mM L-glutamine,
and 2 M forskolin before use. A Western blot using an anti-REDD1
antibody was performed. Using nonconcentrated LVs, transduction of
Schwann cell/DRG neuron cocultures was performed at 7 d after dissec-
tion by incubating the cells with LVs overnight. Cells were then supple-
mented with C media and myelination was induced after 2 d.
A concentrated LV expressing GFP-DDIT4 was used to transduce
myelin-forming Schwann cell/DRG neuron cocultures [clone PLHOS-
100008619 (DQ894159), concentrated LV; Thermo Scientific]. Follow-
ing neuritogenesis, cells were transduced in Cmedia usingmultiplicity of
infection (MOI) 5–10 and myelination was then induced after 2 d.
RT-PCR analysis. Total RNAwas isolated from peripheral nerve using
Trizol (Life Technologies). First-strand cDNAwas prepared from1g of
RNA using the Advantage RT-for-PCR kit (Clontech). Several indepen-
dent pools containing RNA extracted from nerves of 2–5 animals were
used (n  6). The expression of selected mRNAs was determined by
quantitative real-time PCR. Samples were processed in triplicate and
reactions without target cDNA were used as negative control for each
reaction. PCRs were performed on 96-well plates using the Power Sybr
Green PCR Master Mix (Applied Biosystems) and following manufac-
turer’s conditions. Designed probes were used to amplify mouse Ddit4
and the endogenous reference transcripts calnexin. The comparative
Ct method was used. As calibrator, a control sample Ct was chosen
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for each selected transcripts. The Ct (Ct of each normalized
selected transcript minus Ct of the calibrator) was calculated. Ex-
pression levels of each mRNA are indicated as 2Ct values. For
statistical analysis, SD was calculated for triplicate samples of each
reaction and SEM is indicated on the average of the determinations
from different animals.
Morphological analysis. Three to five animals per genotype for each
time point were analyzed. Semithin section and ultrastructural analysis
of sciatic nerves was performed as reported previously (Wrabetz et al.,
20005). To perform morphometric analysis, digitalized images of fiber
cross sections were obtained from corresponding levels of the sciatic
nerves with a Leica DFC300F digital camera with a 100 objective. Five
images per animal were acquired and analyzed with the Leica QWin
software (Leica Microsystem). The g ratio (axon diameter/fiber diame-
ter) was determined by dividing the mean diameter of an axon (without
myelin) by the mean diameter of the same axon including myelin.
Microarray analysis. Total RNA was extracted with Tripure Isolation
Reagent (Roche).
Total RNA was quantified with NanoDrop 2000 spectrophotometer
(Celbio), and its integrity was assessed by running the RNA 6000 Nano
LabChip on the Bioanalyzer 2100 (Agilent Technologies) and selecting
the Eukaryote Total RNA method.
The gene expression profiling was determined using the MouseWG-6
v2 Expression BeadChips (Illumina). Each beadchip can process simul-
taneously six samples, each one investigated for a total of 48,804
transcripts, of which 35,967 are based on the National Center for Bio-
technology Information RefSeq database (Release 22) and 12,837 are
based on UniGene database (Build 199). An amount of 500 ng of total
RNA was reverse transcribed into cRNA and biotin-UTP labeled using
the Illumina TotalPrep RNA Amplification Kit (Applied Biosystems)
according to themanufacturer’s protocol. Fifteen hundred nanograms of
cRNA were then hybridized to the BeadChip Array and stained with
streptavidin-Cy3. All procedures were performed following the manu-
facturer’s instructions. BeadChips have been imaged using the Illumina-
BeadArray Reader, a two-channel 0.8-m-resolution confocal laser
scanner, and the Illumina BeadScan software. The software Illumina-
GenomeStudio v.2011.1 was used to elaborate the fluorescence signal to
a value whose intensity corresponds to the quantity of the respective
transcript in the original sample. The same software was used to assess
the quality controls, which includes the biological specimen control,
hybridization controls, signal generation controls, and negative controls.
For each condition [control andDlg1-null nerves at postnatal day (P) 20,
P40, and 8 months], three biological replicates were tested and a scatter
plot generated for each replicate set. The mean correlation coefficient of
biological replicates was 0.97. Gene expression data were normalized
using the quantile algorithm implemented in the IlluminaGenomeStu-
dio v.2011.1 software, and the transcripts with an intensity value signif-
icantly different from that of background (detection p value,0.01) in at
least one sample were considered in the statistical analyses. A fold change
of 1.5 was chosen as threshold to define the upregulated or downregu-
lated probes in the different comparisons. The overlap of probes upregu-
lated at P20, P40, and 8 months were represented by Venn diagrams
generated using the free on-line software Venny (http://bioinfogp.cnb.
csic.es/tools/venny/index.html; Pirooznia et al., 2007).
Results
Conditional inactivation ofDlg1 in Schwann cells in vivo
provokes transient hypermyelination
To assess whether DLG1 has a negative role on myelination in
vivo in a more physiological context, we generated a Dlg1 fl/fl
(floxed) P0Cre conditional null mouse, with Dlg1-specific ab-
lation in Schwann cells starting at E13.5 (Feltri et al., 1999;
Bolis et al., 2005; Zhou et al., 2008). We previously reported
that Dlg1 expression in the nerve is mainly detected in
Schwann cells and the Dlg1 localization pattern is regulated
during development (Bolino et al., 2004; Bolis et al., 2005,
2009). We confirmed loss of Dlg1 in mutant Schwann cells at
both the mRNA and protein level (Fig. 1A,B). Residual Dlg1
expression in mutant nerve lysates might be explained by the
fact that the nerve also contains perineurial cells, which ex-
press Dlg1 (Fig. 1B).
We analyzed sciatic nerves of Dlg1 fl/fl P0cre mice starting at
P10. Electron microscopy analysis revealed increased myelin
thickness in mutant nerve fibers (Fig. 2A–D). Further, myelin
outfoldings, polyaxonal myelination, and fibers with uncom-
pacted myelin were occasionally observed (Fig. 2E–G). In addi-
tion to occasional myelin outfoldings, hypermyelinated fibers
Figure 1. Loss of Dlg1 in Dlg1 fl/fl P0Cre and Dlg1 fl/P0Cre mice. A, Quantitative RT-PCR
analysis from Dlg1 fl/fl P0Cre nerves and controls at P20 shows a decrease of Dlg1mRNA60%
in themutants. ***p 0.001.B,Western blot analysis on lysates fromDlg1 fl/fl P0Cre,Dlg1 fl/
P0Cre, and controls (fl/) at both P20 and P60 demonstrates downregulation of Dlg1 at the
protein level. Cx, Calnexin. All data represent means SEM.
Figure 2. Ultrastructural analysis of Dlg1 fl/fl P0Cre sciatic nerves at P10. A, C, Wild-type
nerve fibers. B, D, D’, D, Dlg1 fl/fl P0Cre mutant nerves show fibers with increased myelin
thickness. E, F, G, Myelin outfoldings (E), polyaxonal myelination (F ), and uncompacted my-
elin (G) were occasionally observed inmutant nerves.H, I, Increasedmyelin thickness at P45 in
Dlg1 fl/fl P0Cre nerves. J, J’, Occasional myelin outfoldings in Dlg1 fl/fl P0Cre nerves. Scale bars:
A–G, 1m; H–J’, 2m.
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were also evident at P20 and P45 (Fig. 2H–J’). The increase of
myelin thickness in mutant nerves was further assessed by mor-
phometric analysis (Fig. 3). The mean g-ratio value of mutant
nerve fibers at P20 was significantly lower compared with wild-
type nerves, thus confirming hypermyelination inDlg1 fl/fl P0Cre
nerves (Fig. 3A,B). Increased Krox20 (at P10 and P20) and P0
myelin protein expression (at P20) inmutant nerves further sup-
ported enhanced myelination (Fig. 4A,B; data not shown). Fi-
nally, the number of myelinated fibers at P1–P2 was similar
between mutant and wild-type sciatic nerves as assessed by both
immunohistochemistry and morphological analysis (data not
shown).
DLG1 is believed to potentiate PTEN phospholipid phospha-
tase activity toward PIP3, thus negatively modulating the PI3K/
AKT signaling pathway (Cotter et al., 2010). Although PTEN
expression levels were similar betweenmutant and control nerves
at P10 (data not shown), P20, and P60 (Fig. 4D), AKT phosphor-
ylation at S473 was increased in Dlg1 fl/fl P0Cre nerves at P10 but
not at P20, suggesting that the hypermyelinating signal is tempo-
rary (Fig. 4C; data not shown).
Figure3. Transienthypermyelination in conditionalDlg1 fl/fl P0Crenerves.A, Quantificationof theg ratio as a functionof axonal diameter inDlg1 fl/fl P0Cre sciatic nerves and controls at P20 shows
increased myelin thickness in mutant nerves (Dlg1 fl/fl P0Cre, 0.664 0.013; WT, 0.703 0.002, p 0.037 on means, n 1500 fibers, n 3 animals per genotype). B, Axonal diameter
distribution at P20. C, Quantification of the g ratio as a function of axonal diameter inDlg1 fl/fl P0Cre sciatic nerves and controls at P90 (Dlg1 fl/fl P0Cre, 0.674 0.034;WT, 0.670 0.035; p 0.475
onmeans, n 1600 fibers, n 4 animals per genotype).D, Axonal diameter distribution at P90. E, Quantification of the g ratio as a function of axonal diameter inDlg1 fl/ P0Cre sciatic nerves and
control sciatic nerves at P90 (Dlg1 fl/ P0Cre, 0.689 0.003; WT, 0.682 0.01; p 0.55 on means, n 3000 fibers, n 5 animals per genotype). F, Axonal diameter distribution at P90. G,
Quantification of the g ratio as a function of axonal diameter in Dlg1 fl/fl P0Cre sciatic nerves and control sciatic nerves at 6months (Dlg1 fl/fl P0Cre, 0.693 0.019;WT, 0.680 0.019; p 0.61 on
means, n 1500 fibers, n 3 animals per genotype).H, Axonal diameter distribution at 6 months. C, E, G, All show normal myelin thickness in mutant nerves. All data represent means SEM.
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In fact, when analyzed at later time points, Dlg1-null nerves
displayed normal myelination. At P90 and at 6 months of age,
mean g-ratio values were similar between mutant and control
nerves (Fig. 3C,D,G,H). Dlg1 expression level increases during
postnatal development andmyelination (Bolis et al., 2009; Cotter
et al., 2010). To rule out low efficiency of Cre-mediated recom-
bination in Dlg1 fl/fl P0Cre nerves, we also
analyzed nerves fromDlg1 f l/P0Cremice
at P90 (Fig. 3E,F). Dlg1 fl/ P0Cre condi-
tional knockout mice are compound
heterozygous for a floxed allele and a null
allele (Dlg1 is lost in all cells) generated by
crossing aDlg1 fl/mouse with a CMVCre
transgenic mouse. Thus, we found that
also Dlg1 fl/ P0Cre as Dlg1 fl/fl P0Cre
nerve fibers display mean G-ratio values
similar to control nerves (Fig. 4E,F). In
conclusion, our findings suggest that loss
of Dlg1 in Schwann cells in vivo leads to a
transient hypermyelinating phenotype
and that DLG1 acts as a temporal negative
regulator of myelination in physiological
conditions.
DDIT4/REDD1/RTP801 expression is
upregulated inDlg1 fl/fl P0Cre nerves
We then hypothesized that the transient
effect on myelination might be due to the
upregulation of another negative regula-
tor of myelination or alternatively to the
downregulation of a positive regulator of
myelination. To explore these possibili-
ties, we performed a microarray analysis
using mRNA from Dlg1 fl/fl P0Cre sciatic
nerves and controls at P20, P40, and 8
months. We selected transcripts differen-
tially expressed of at least 1.5 folds (p 
0.01) in mutant nerves compared with
wild type at the different time points ana-
lyzed. We also selected the mRNAs being
differentially expressed in mutant nerves
compared with controls and shared be-
tween P20 and P40 (when hypermyelina-
tion is still present but phosphorylation of
AKT declines in Dlg1 fl/fl P0Cre nerves),
and between P40 and 8-month-old mu-
tant nerves. Interestingly, the expression
of other adaptors with similar function or
scaffolding molecules belonging to the
MAGUK (membrane-associated guanylate
kinase) family, such as PSD93, PSD95, and
SAP102, was normal (Sheng and Sala,
2001). Surprisingly, among the five tran-
scripts upregulated in mutant nerves and
shared between P20 and P40 mutants, we
found the Ddit4 gene (Fig. 5A,B; Table 1),
which encodes REDD1/RTP801, a known
negative regulator of mTORC1 and there-
fore an interesting candidate (Abraham,
2005; Ellisen, 2005; Maiese et al., 2013).
DDIT4-mediated regulation of mTORC1
activity has different outcomes depending
on the cell type and the cellular context. In
mammalian cells,DDIT4 expression is mainly induced in response
tobothhypoxia andenergy stress, followingAMPK(AMP-activated
protein kinase) activation. Further, cells defective for DDIT4 have
increasedmTORC1 activation and dysregulation of cell growth and
cell size (Sofer et al., 2005; Yoshida et al., 2010; Cam andHoughton,
2011). More recently, it has been suggested that loss of DDIT4 in
Figure 4. Enhancedmyelination inDlg1 fl/fl P0Cre nerves at P10 andP20.A,Western blot analysis on lysates frommutant and control
sciatic nerves shows increased krox20 expression in the mutant at P20 (13%, p 0.043, on 3 animals per genotype). B, Increased
expressionof P0,myelin protein zero, inmutant nerves comparedwith controls at P20 supports increasedmyelin thickness (37%,p
0.0012, on 3 animals per genotype).C, IncreasedAKTphosphorylation at S473was observed inmutant nerves at P10 (15%,p0.05,
3 animals per genotype).D, PTEN expression levels are similar betweenmutant and control nerves at both P20 andP60. Cx, Calnexin.
Figure5. UpregulationofDdit4mRNA inDlg1 fl/fl P0Crenerves.A,B, Venndiagrams showingupregulatednumber of probes for
mRNA transcripts inDlg1 fl/fl P0Cre nerves comparedwith control nerves and shared between P20 and P40 nerves (A) and between
P40 and 8-month-old nerves (B). C, DDIT4 is expressed in rat purified Schwann cells and its level decreases upon NRG1 stimulation
for 15 min when phosphorylation of AKT at S473 increases. Cx, Calnexin. D, Quantitative RT-PCR analysis of Ddit4 and Dlg1
expression in wild-type nerves during development at P2, P10, P20, and P40, using n 3 different pools per time point. E, F,
Relative amount of Dlg1 and phosphorylated AKT during postnatal myelination in mouse sciatic nerves. Pools of nerves from
different animals were used per time point in two independent experiments. G, Along with Ddit4 upregulation, HIF3A expression
also increased at both the mRNA (Table 1) and at the protein level in Dlg1 fl/fl P0Cre nerves.
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Table 1. Genes differentially expressed in Dlg1 fl/fl P0Cre nerves compared with
controls at P20, P40, and 8months




ILMN_2718266 Fkbp5 355 25.5 1304.6 481.1 2.86
ILMN_2649671 Ipas 454.1 57.5 1535.1 551.7 2.74
ILMN_2588249 S3-12 907.4 61.2 2443.6 642.9 2.47
ILMN_2969172 Tmem87a 142 6.1 432.4 145.3 2.42
ILMN_2822000 8430417G17Rik 260.6 23.6 736.5 268.3 2.26
ILMN_1229216 Zbtb16 221.5 13 577.5 197.7 2.19
ILMN_2701664 Dsip1 1169.3 203.9 2978.2 1126.5 2.04
ILMN_1246876 Kit 422 90.3 964.3 321.8 2.04
ILMN_1245464 Slc9a3 812.2 81.4 1816.3 533.8 2.03
ILMN_2466121 Twistnb 197.2 71.3 359.1 36.6 1.93
ILMN_1241260 D330011G23Rik 109.6 2.6 249.4 75.9 1.89
ILMN_1234929 Arid5b 798 103.2 1633.8 465.2 1.88
ILMN_2636624 8430417G17Rik 139.1 6.9 307.2 103.4 1.84
ILMN_1219154 Mt2 528.1 62.2 1103.5 359.5 1.83
ILMN_2733542 Fbxl3a 235.4 10.3 556.9 280 1.83
ILMN_2987862 Per2 1032 183.8 1994.5 575.5 1.76
ILMN_2772077 Bok 1945.6 184.6 3689.2 1074.5 1.76
ILMN_1231779 Twistnb 176.9 58.8 293.3 12 1.74
ILMN_3150811 Tsc22d3 9571.7 1481.2 18,899 6120.9 1.73
ILMN_2734142 Snta1 3141.2 167.9 5759.4 1349.8 1.72
ILMN_2636666 Prodh 871.5 70.1 1579.5 333.4 1.71
ILMN_2514305 Za20d1 496.5 41.7 876.2 136.1 1.71
ILMN_2909150 Ctgf 1696.6 243.1 3093.6 886.1 1.69
ILMN_1229667 Slc43a1 411.3 27.8 726.3 132 1.69
ILMN_2672698 Rassf4 1017.8 99.2 1761.1 318.7 1.68
ILMN_1238215 Ctgf 1141.8 175.6 2043.9 585.5 1.67
ILMN_1240671 LOC382058 262.9 40.6 515.2 200.1 1.67
ILMN_3122383 Otud7b 1594.9 119.1 2811.8 607.7 1.67
ILMN_2689160 Ranbp9 983.4 26 1738.2 378.7 1.67
ILMN_1259322 Pdk4 619.6 225.9 1014.8 282.4 1.67
ILMN_2770894 Map3k6 343 12.1 600.2 106.9 1.66
ILMN_3046773 Otud7b 364.8 21 639.7 122.7 1.66
ILMN_1243942 LOC382190 231.8 118.9 371.4 131.3 1.63
ILMN_2430906 2310051E17Rik 734.7 31.8 1257.5 276.8 1.62
ILMN_2760494 Hif3a 137.4 9 247.1 59.8 1.61
ILMN_2693835 Arrdc2 420.1 52.7 735 188.4 1.61
ILMN_2947292 Map3k6 328.7 13.8 563.8 113.3 1.61
ILMN_2987863 Per2 791.2 147.7 1366.6 369.2 1.61
ILMN_1237404 Bok 219.6 24.1 372.4 73.8 1.60
ILMN_2768972 BC055107 3198 387.7 5351.7 1182.9 1.60
ILMN_3163340 Drbp1 299.1 2.6 516.1 114.6 1.59
ILMN_2964560 Cd163 741.2 33.9 1195.6 138.7 1.58
ILMN_1218051 A630086H07Rik 2709.3 223.8 4340.4 567.4 1.58
ILMN_2838308 Fmo1 2734.5 359 4384.6 747.8 1.58
ILMN_1253819 Prkar2b 2329.6 390.9 3572.9 200.9 1.57
ILMN_2944508 Bglap2 263.4 105.6 576.8 384.5 1.57
ILMN_3136744 Sesn1 6700 226.8 10,904.7 1976.8 1.57
ILMN_1225370 2410039M03Rik 4132.3 249.6 7034.8 1790.3 1.57
ILMN_1254031 Bteb1 7259.8 462.6 11,955.6 2839.1 1.56
ILMN_2723891 Egfl5 1677.1 107 2630.7 339.8 1.55
ILMN_2894211 8430408G22Rik 381.1 110.7 610.4 166 1.54
ILMN_2993109 Ddit4 3411 713.9 6097.5 2258.9 1.53
ILMN_2688681 Npm3 310.9 50.9 502.3 119.6 1.52
ILMN_2636738 Fstl3 468.3 29.6 739.6 128.2 1.51
ILMN_2476733 1200016E24Rik 2417.1 182.9 3825.8 793.8 1.51
ILMN_2753912 Pdgfc 231.3 12.5 367.9 62.7 1.51
ILMN_2908846 Iqgap2 1290.4 89.1 1959.7 195.4 1.50
ILMN_1221999 Cldn22 972.2 172 1451.5 182.8 1.50
ILMN_1217629 Itgae 371.7 11.5 585 101.8 1.50
P40 upregulated probes
ILMN_2838965 4930455C21Rik 484.3 249.4 689.4 201.2 3.37
ILMN_2965669 Xlr4a 443.5 168.4 584.1 69.3 2.77
(Table continues.)
Table 1. Continued
Illumina probe ID Gene symbol Mean SEM in WT Mean SEM in KO
Fold
change
ILMN_2825109 Zfp330 720.6 291 828.9 283.5 2.63
ILMN_2543433 1110030C22Rik 831.5 211.1 1035.3 383.3 2.32
ILMN_2672772 Abhd1 225 63.3 255.8 67.8 2.04
ILMN_2676379 Pon1 459.8 109 553.5 425 1.93
ILMN_2729513 Hbb-b2 121.5 5 149.2 98.3 1.89
ILMN_2672778 Abhd1 222.1 62.1 235.8 51.2 1.86
ILMN_3065459 Mup2 1662.1 283.3 2009.8 1358.7 1.83
ILMN_2953807 LOC620807 1011.4 135.7 1243.1 886.1 1.81
ILMN_1246772 B430305P08Rik 1232.5 230 1282.7 200.4 1.81
ILMN_1245678 Abhd1 291.7 72.5 303.8 75.1 1.79
ILMN_1234241 1110025G12Rik 302.9 75.4 311.1 44.1 1.78
ILMN_2875730 Mup1 3058 520.6 3767.4 2804 1.77
ILMN_1229990 Agxt2l1 211.4 55.5 217.4 39 1.76
ILMN_3111685 Acsm3 217 38 241.4 135.8 1.74
ILMN_3143404 Mup2 936.4 141.5 1135.2 831.8 1.74
ILMN_2893879 Gdpd3 880.3 278.4 929.1 470.4 1.74
ILMN_1223046 Cdgap 184.5 38.7 190.7 37.5 1.73
ILMN_2648669 Gpnmb 1522.5 97.2 1568.9 348.3 1.71
ILMN_2627318 4930455C21Rik 245.9 50.6 249.1 35 1.70
ILMN_2730208 Mup1 9221.5 1425.1 10,992.6 8277.7 1.70
ILMN_1225291 B230354O11Rik 1162.1 615.7 1010 51.5 1.69
ILMN_2540464 LOC381904 191 11 236.2 247.8 1.66
ILMN_1229454 Cuedc1 398.8 68.7 395 100.9 1.63
ILMN_1216231 Scoc 521.4 95.8 514.7 132.6 1.63
ILMN_3135697 1200003I07Rik 736.3 167 704 76.2 1.63
ILMN_1225130 LOC385909 123.5 9.9 125.3 17.6 1.62
ILMN_2702903 Cyp2f2 521.2 100.3 512 145.4 1.62
ILMN_2944824 Hp 2262.5 449.5 2240.5 892.2 1.61
ILMN_1259322 Pdk4 564.4 95.3 546.1 123.2 1.58
ILMN_2993109 Ddit4 1800.5 103.5 1833.8 905.5 1.57
ILMN_1251114 BC002216 208.9 111.5 192.6 111.4 1.54
ILMN_2668509 Hp 1267 184.2 1239.4 519.8 1.54
ILMN_1241214 Myh4 168.6 38.2 205.9 235 1.54
ILMN_2822000 8430417G17Rik 492.1 63.7 469.4 96.5 1.52
ILMN_2772273 Cldn22 769 202.8 701.6 142 1.52
ILMN_2676012 Mybpc2 309.1 124 391.4 517.9 1.52
ILMN_2458376 5330426P16Rik 159 14.1 155.1 39.6 1.52
ILMN_3163340 Drbp1 361.6 103.8 358.9 203.2 1.51
ILMN_1221146 4930443F05Rik 275.5 73.7 254.3 38.4 1.51
8 month upregulated probes
ILMN_1215076 F830002E14Rik 7663.5 2723.4 24,735.2 5724 3.50
ILMN_2825109 Zfp330 439.7 293.1 978.7 29.4 3.29
ILMN_1235372 Hbb-b1 1377.8 724.2 4437.8 2371.4 2.99
ILMN_2544056 Hbb-b1 4736.6 2157.2 18,237.3 11,394.8 2.71
ILMN_2675874 Alas2 676.8 205.9 2201.9 1242.8 2.35
ILMN_2875730 Mup1 680.5 443 2320.3 1725.9 2.24
ILMN_1241039 2510042H12Rik 191.8 47.6 593.6 338.5 2.22
ILMN_1228607 Igk-V1 234.1 44.8 1263.1 1058.6 2.19
ILMN_2730208 Mup1 2126.8 1515.1 7288.1 5425.7 2.17
ILMN_1255462 Hbb-b1 29,863.5 15,173.6 52,608.5 10,818.9 2.16
ILMN_1250715 LOC381774 198.2 45.3 1086.1 918.2 2.14
ILMN_2539917 LOC384538 202.2 42.5 578.9 302.6 2.10
ILMN_3065459 Mup2 366.9 198.4 1114.9 745.9 2.10
ILMN_2631259 Igk-V1 166.1 10.8 455.4 251 1.97
ILMN_2769490 5430435G22Rik 445.6 107.8 822.6 207.2 1.84
ILMN_1234241 1110025G12Rik 576.5 191.6 1029.1 364.1 1.81
ILMN_2953807 LOC620807 303.4 141.1 691.9 392.2 1.80
ILMN_1216231 Scoc 350.1 97 595.6 14.3 1.78
ILMN_1256775 Thrsp 1232.6 277 2694.8 1130.4 1.76
ILMN_2484987 Man2b1 1189.2 450.4 1645.7 43.7 1.76
ILMN_1239117 Hbb-b1 31,967.3 12,718.4 50,064.2 9739.4 1.76
ILMN_2502614 Ttc15 144.8 31.6 261.1 34.2 1.76
ILMN_1216452 Hbb-b1 31,229.4 12,824.9 49,044.9 12,004.8 1.74
(Table continues.)
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neurons affects survival and the timing of neuronal differentiation
and migration (Shoshani et al., 2002; Brafman et al., 2004; Malage-
lada et al., 2011).
To assess the role of DDIT4 in the PNS, we first determined
its expression in vitro and in vivo. We found that DDIT4 is
expressed in rat purified Schwann cells (Fig. 5C), whereas in
vivo in the nerve, Ddit4 mRNA expression is significantly up-
regulated between P2 and P10 and then rapidly declines be-
tween P10 and P20 (Fig. 5D). Interestingly, NRG1 stimulation
of rat purified Schwann cells reduces DDIT4 expression along
with an increase of AKT phosphorylation at S473 (Fig. 5C).
This finding indicates that DDIT4 expression likely precedes
the peak of AKT activation both in vitro and in vivo (Fig.
5D–F ). Unfortunately, DDIT4 protein expression was not fur-
ther investigated in vivo, as available antibodies were not spe-
cific when used on nerve.
The upregulation of the Ddit4 gene in Dlg1 fl/fl P0Cre nerves
was further confirmed by quantitative RT-PCR analysis (con-
trols, 1  0.084; Dlg1 fl/fl P0Cre, 1.424  0.091; p  0.005, on
seven pools of three animals per genotype). To assess whether the
upregulation ofDdit4 expressionwas a consequence of the loss of
Dlg1 or rather a general phenomenon associated with hypermy-
elination mediated by the PI3K/AKT/mTOR pathway, we ana-
lyzed Ddit4mRNA expression in Vim-null nerves, characterized
by increased NRG1 type III signaling leading to sustained hyper-
myelination (Triolo et al., 2012). In Vim-null nerves, Ddit4 ex-
pressionwas similar to that of control (controls, 1.22 0.17;Vim
null, 1.07  0.091; p  0.578, on seven
pools of three animals per genotype), sug-
gesting that the upregulation ofDdit4 ob-
served in Dlg1 fl/fl P0Cre nerves is due to
the loss of Dlg1 rather than to a general
event linked to hypermyelination.
Interestingly, along with increased
expression of Ddit4, we also found that
HIF3 (hypoxia inducible factor) is sig-
nificantly upregulated in Dlg1 fl/fl P0Cre
nerves at P20 at both the mRNA (Table 1)
and protein level (Fig. 5G). In addition to
hypoxia, also mTORC1 can induce HIF1
andDDIT4 expression, thus eliciting a neg-
ative feedback loop on its own activity
(Ellisen, 2005; Schwarzer et al., 2005). Al-
though the role of HIF3 still remains to be
assessed (Hatanaka et al., 2009; Tanaka et
al., 2009), it can be hypothesized that fol-
lowing AKT/mTOR activation, HIF3 in-
duces DDIT4 expression in Dlg1 fl/fl P0Cre
nerves, which negatively regulates the
mTOR pathway, leading to normal myelin
thickness at later stages.
DDIT4 is a negative regulator of
myelination in vitro
Because of its role as a negative regulator
of mTORC1 in other systems, DDIT4
could potentially negatively regulate myeli-
nation in the PNS. To investigate DDIT4
function inmyelination, we first established
myelin-forming Schwann cell/DRG neu-
rons cocultures from Dlg1 fl/fl P0Cre and
control mouse embryos at E13.5. To in-
crease P0Cre-mediated recombination in
Figure 6. Increased myelination in Dlg1 fl/fl P0Cre Schwann cell/DRG neuron cocultures. A, Cocultures established from
Dlg1 fl/fl P0Cre embryos produced more myelinated segments compared with control cultures. Cells were cultured for
10 –15 d in NB and myelination was induced for 7 or 15 d with ascorbic acid. B, In all conditions, an increase of	40% of
MBP-positive fibers was scored in mutant cultures, n  10 covers/DRG per genotype, four different experiments.
***p 0.001, data represent means SEM. C, Western blot analysis on lysates from mutant and wild-type cocultures
shows decreased Dlg1 expression and increased phosphorylation of AKT (S473) in mutant cells, which is consistent with in
vivo findings. D, DDIT4 expression is upregulated in Dlg1 fl/fl P0Cre cultures (WT, 0.616; Dlg1 fl/fl P0Cre, 0.8963,45%).
Lysates from pools of at least 10 different covers/DRG per genotype were loaded. Cx, Calnexin. Scale bar, 10m.
Table 1. Continued
Illumina probe ID Gene symbol Mean SEM in WT Mean SEM in KO
Fold
change
ILMN_2777462 Adpn 525.7 116.7 1041.7 452.2 1.71
ILMN_1226935 Orm1 835.4 125.6 1459.3 264.6 1.71
ILMN_3143404 Mup2 286.6 138 696.5 464.7 1.70
ILMN_1226583 LOC384422 94.8 0.8 205.9 97.4 1.68
ILMN_2545963 Hbb-b1 37,692.8 14,022.3 56,316.9 8010.8 1.68
ILMN_1215901 Agpat2 1235.1 176.8 2058.4 255.1 1.66
ILMN_1255372 LOC386321 136.1 1.7 251.2 56.2 1.66
ILMN_1225291 B230354O11Rik 1667.1 576.7 2453.2 606 1.63
ILMN_1230696 Igl-V1 115.6 1.4 317.8 221.5 1.62
ILMN_1245146 Igl-V1 217.8 35.1 954.5 830.8 1.62
ILMN_1228020 1500010G04Rik 428.2 87 672.4 31.5 1.60
ILMN_1212702 Hba-a1 34,308.3 10,714.2 51,271.2 9519.5 1.58
ILMN_2616584 Ppp1r1a 595.2 173.9 958.3 272.7 1.57
ILMN_1223244 Hbb-b1 37,626.7 12,767.1 53,585 9091.1 1.55
ILMN_1224207 D630016K15Rik 195.9 44.9 330.8 101.7 1.55
ILMN_1247691 Hes1 711.8 37 1112.6 62 1.55
ILMN_1229203 Hbb-b1 40,393.6 12960.1 56,895.9 8213.5 1.53
ILMN_2740151 Chpt1 1799.6 168.8 2769.5 274.8 1.53
ILMN_2777535 Ptplb 742.2 45.5 1178.1 219.8 1.53
ILMN_2692644 BC054059 839.2 197.8 1400.1 438.8 1.53
ILMN_2599794 Apoc1 723.1 172.6 1326.7 646.7 1.52
ILMN_2886260 Foxc1 773.4 104 1172 124.1 1.52
ILMN_1219915 Dgat2 6132.1 630.8 9250.4 828.8 1.51
ILMN_1236603 LOC386169 228.6 22.5 350.9 21.6 1.51
ILMN_1226472 Retnla 2319.5 311.7 3593 748.1 1.50
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vitro,Dlg1 fl/fl P0Cre explants were cultured for 15 d in NBmedium
before inducing differentiation by ascorbic acid treatment. Dlg1 fl/fl
P0Cre explants produced significantly more myelinated segments
after 7 and 15 d of ascorbic acid treatment compared with control,
thus reproducing the hypermyelination observed in vivo (Fig.
6A,B). Consistent with this finding, AKT phosphorylation at S473
was increased in Dlg1 fl/fl P0Cre explants (Fig. 6C). Interestingly,
DDIT4 expression was upregulated inDlg1 fl/fl P0Cre explants (Fig.
6D).
To assess the role of DDIT4, we downregulatedDdit4 expres-
sion by means of shRNA LV transduction in either wild-type or
Dlg1-null explants. In this case, Dlg1 fl/fl P0Cre and wild-type ex-
plants were infected after 7 d in culture and ascorbic acid was
provided at day 10 for 7 d. Ablation ofDdit4 in wild-type explants
produced significantly more myelinated segments compared
with scramble-treated controls (Fig. 7A–C). Interestingly, down-
regulation ofDdit4 expression inDlg1 fl/fl P0Cre explants resulted
in more myelin segments compared with both Dlg1 fl/fl P0Cre
explants transduced with a scramble sequence and to wild-type
explants (Fig. 7A–C). Finally, we overexpressed GFP-DDIT4 in
premyelinating cocultures in which neuritogenesis was already
achieved. Cultures transduced with GFP-DDIT4 LVs yielded sig-
nificantly fewer myelinated segments compared with GFP trans-
duced cultures (Fig. 7D,E). Overall, these findings suggest that
DDIT4 is a negative regulator of myelination in vitro.
Loss of Ddit4 in vivo causes sustained hypermyelination in
the PNS
To assess the role of DDIT4 in vivo, we analyzed sciatic nerves of
Ddit4-null mice starting at P10 (Shoshani et al., 2002; Yoshida et
al., 2010). In Ddit4-null nerves at P10, we observed fibers with
increased myelin thickness, whereas the number of myelinated
fibers was similar between mutant and control nerves (Fig. 8A).
Additional signs of enhanced or ectopic myelination, such as
polyaxonal myelination and myelinated fibers 1 m were not
evident. G-ratio analysis performed at P30 and at P90 confirmed
increasedmyelin thickness inDdit4-null nerves, whereas the total
number ofmyelinated fibers and fiber diameter distributionwere
similar between mutant and control nerves (Fig. 8C–H). Inter-
estingly, signs of focal hypermyelination, such as tomacula or
myelin outfoldings, which are linked to PI3K/AKT/mTOR acti-
Figure 7. DDIT4 is a negative regulator ofmyelination in vitro inmyelin-forming Schwann cell/DRG neuron cocultures.A, Efficiency of DDIT4 downregulation usingDdit4 shRNA LV on purified rat
Schwann cells. Cx, Calnexin. B, C, Wild-type cultures transduced with LV carrying GFP-Ddit4 shRNA produced more myelinated segments compared with scramble (GFP-tag)-treated cultures.
Similarly, cocultures established from Dlg1 fl/fl P0Cre mouse embryos transduced with Ddit4 shRNA LV yieldedmore myelinated segments compared with Dlg1 fl/fl P0Cre cultures transduced with a
scramble sequence. Note thatDlg1 fl/fl P0Cre explants inBproduced19%moreMBP segments than control explants andnot 40%as reported in Figure 7. In this experiment explantswere transduced
after 7 d of NB treatment. WT NT (not transduced) and Dlg1 KO, p 0.027; WT SCR (scramble) andWT shDdit4, p 0.0001; WT SCR and Dlg1 KO shDdit4, p 0.0006; Dlg1 KO shDdit4 and Dlg1
KOSCR,p0.0356;WTSCRandDlg1KOSCR,p0.0274.D,E, TheoverexpressionofGFP-DDIT4bymeansof LV transduction inwild-type cultures significantly decreased thenumber ofmyelinated
segments. MBP is myelin basic protein. Themean of MBP-positive segments scored in the cultures is reported SEM. Experiments have been scored usingn 10 different DRGs per condition.
Scale bars, 10m.
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vation, were not observed inDdit4-null nerves at any time points
analyzed.
DDIT4 activates TSC1/2 GAPs and negatively regulates
mTORC1 (Abraham, 2005; Ellisen, 2005; Maiese et al., 2013). To
investigate the extent of mTORC1 activation in Ddit4-null
nerves, we looked at the phosphorylation of the S6 kinase, a
downstream target of mTORC1.We found that phosphorylation
of S6 was significantly increased in Ddit4-null nerves, suggesting
activation of the mTOR pathway (Fig.
8B). Phosphorylation of AKT at residue
473 was increased in mutant nerves, con-
sistent with mTORC2 activation by
mTORC1 and the positive feedback loop
on AKT phosphorylation. Further, AKT
phosphorylation at T308 was slightly de-
creased in the mutant, likely as the result
of a negative feedback loop on tyrosine
kinase receptors and PDK1 activation
(Harrington et al., 2005).
In conclusion, our results support a
role for DDIT4 as a negative regulator of
myelination, as its loss both in vitro and in
vivo results in hypermyelination.
Discussion
During development, myelination is pro-
moted by a plethora of positive signals,
which must be tightly modulated to en-
sure a correct timing for myelination and
to adjust myelin thickness to the axonal
diameter.
In the PNS, axonal NRG1 type III dic-
tates the differentiating fate of a Schwann
cell and, above a certain threshold, the
amount of myelin that has to be pro-
duced. NRG1 type III binds to erbB2/B3
receptors in Schwann cells, of which the
PI3K/AKT pathway is one of the main
downstream effectors (Nave and Salzer,
2006; Pereira et al., 2012). DLG1 has been
recently suggested as the main brake on
myelination in the PNS by acting on the
modulation of the PI3K/AKT pathway
(Cotter et al., 2010;Macklin, 2010). DLG1
is believed to potentiate PTEN enzymatic
activity toward PIP3, which contributes to
AKT activation (Cotter et al., 2010). In-
deed, Cotter et al. (2010) reported that
acute postnatal downregulation of Dlg1
expression by injecting LVs in sciatic
nerves at both P3 and P20 results in in-
creased myelin thickness at 2 months and
3 weeks postinjection, respectively. Loss
of DLG1 should lead to decreased PTEN
activity, increased PIP3 levels, sustained
AKT activation, and hypermyelination.
Consistent with the previous report,
we found that nerves frommice withDlg1
conditional inactivation in Schwann cells
are hypermyelinated, with a mild but sig-
nificant increase in myelin thickness dur-
ing postnatal development. However, in
contrast with previous findings, adultDlg1-
null nerves displayed normal myelin thick-
ness, suggesting that the hypermyelination is transient and related to
the developmental stage. Further, Cotter et al. (2010) reported that
DLG1 regulates PTEN stability and amount in vitro. However, in
Dlg1-null nerves we observed normal PTEN expression. Our results
might be explained by the fact that, when theDLG1 is lost in amore
physiological context, PTEN enzymatic activity rather than its ex-
pression level may change, as already reported for other enzymes
Figure 8. Loss of Ddit4 in vivo leads to sustained hypermyelination with increasedmyelin thickness in the nerve. A, Ultrastruc-
tural analysis of Ddit4-null sciatic nerves at P10 shows fibers with increased myelin thickness. B, Western blot analysis showing
increased S6 inDdit4-null nerves (50%;WT, 0.480.043;Ddit4-null, 0.980.069) andAKT (S473), anddecreasedAKT (T308)
phosphorylation in Ddit4-null nerves (S473 phosphorylation:30%; WT, 0.725 0.021; Ddit4-null, 0.94 0.001; T308 phos-
phorylation:10%, WT, 0.64 0.092; Ddit4-null, 0.50 0.046) compared with controls, suggesting mTORC1 activation. Cx,
Calnexin.C, Quantificationof theg ratio as a functionof axonal diameter inDdit4-null sciatic nerves and control sciatic nerves at P30
(Ddit4-null, 0.631 0.009; WT, 0.672 0.007, p 0.026 on means, n 2000 fibers, n 4 animals per genotype) shows
increased myelin thickness in mutant nerves. D, Axonal diameter distribution at P30. E, Quantification of the g ratio as a function
of axonal diameter in Ddit4-null sciatic nerves and control sciatic nerves at P90 (Ddit4-null, 0.652 0.004; WT, 0.680 0.007,
p 0.02 onmeans, n 1500 fibers, n 3 animals per genotype) shows increasedmyelin thickness inmutant nerves. F, Axonal
diameter distribution at P90.G,H, Comparison betweenmeang-ratio values ofDlg1 fl/fl P0Cre andDdit4-null nerves at P30 (G) and
at P90 (H ) indicates that hypermyelination is transient in Dlg1 fl/fl P0Cre whereas represents a sustained phenotype in Ddit4-null
nerves. At P30,meang-ratio value is 0.6490.005 forDlg1 fl/fl P0Crenerves and0.6780.01 for control nerves (n1700 fibers,
3 animals). Scale bar, 2m. All data represent means SEM.
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regulating phosphatidylinositide (PI) metabolism (Zolov et al.,
2012).
Interestingly, we also found that in Dlg1-null nerves Ddit4
expression is upregulated. DDIT4/REDD1/RTP801 attracted our
attention as DDIT4 is a known negative regulator of the mTOR
pathway in other cells (Abraham, 2005; Ellisen, 2005; Maiese et
al., 2013) and thus a potential negative regulator of myelination
mediated by the PI3K-AKT pathway. This protein was indepen-
dently identified in human as direct transcriptional target of HIF
and in Drosophila as Shylla and Charydbis, two orthologues of
Ddit4, encoding TSC-dependent potent suppressors of PI3K
(Sofer et al., 2005; Yoshida et al., 2010; Cam and Houghton,
2011). While the regulation of mTOR by PI3K/AKT does not
require DDIT4 under nutrients and growth factor stimulation,
following hypoxia and energy stress mTOR activity is dependent
on DDIT4. In addition, DDIT4 is involved in the control of cell
size and cell growth, as overexpression or RNAi-mediated inhi-
bition of DDIT4 in bothDrosophila andmammalian cells impair
cell size and growth. Interestingly, in neurons DDIT4 role varies
depending on the cellular context. DDIT4 protects neurons from
apoptosis following oxidative stress, may promote death of post-
mitotic neurons, and regulates the timing of cortical neurogen-
esis and neuron migration (Malagelada et al., 2011).
Given its role as negative regulator of the AKT/mTOR path-
way in other cells, DDIT4 represented a novel candidate to neg-
atively regulate PNS myelination. Indeed we found that the
downregulation ofDdit4 expression inmyelin-forming Schwann
cell/DRG neuron cocultures enhances myelination. Further,
overexpression of DDIT4 in a coculture system led to decreased
myelination. In addition, we confirmed that DDIT4 is a negative
regulator of myelination in vivo, as Ddit4-null nerves displayed
enhanced mTORC1 activation and increased myelin thickness
during development as well as in adult nerves.
DDIT4 and DLG1, two negative regulators of myelination
The fact that DLG1 andDDIT4 act on the same pathway and that
Ddit4 is upregulated inDlg1 fl/fl P0Cre nerves suggests that DLG1
and DDIT4 are functionally linked.
In cultured neurons, DDIT4 levels increase soon after NGF
stimulation, but rapidly decline when neuronal differentiation
takes place (Malagelada et al., 2011). Moreover, it has been re-
cently reported that in vitro and in vivo interference with DDIT4
expression promotes cell cycle exit and accelerates neuronal dif-
ferentiation (Malagelada et al., 2011). To assess whether DDIT4
may also control the timing of differentiation andmyelination at
early stages in Schwann cells, we measuredDdit4 expression pat-
tern during postnatal nerve development. We found that Ddit4
expression reaches its maximum level between P2 and P10, and
then rapidly drops between P10 and P20. Thus theDdit4 expres-
sion level anticipates the peak of AKT phosphorylation and acti-
vation and of DLG1 expression/stability. Therefore, it can be
speculated that, by analogy with neurons, DDIT4 may regulate
the timing of Schwann cell myelination by preceding the peak of
AKT activation and of DLG1 expression.
In Ddit4-null nerves, mTORC1 activation is enhanced, lead-
ing to sustained hypermyelination and increased myelin thick-
ness. Ddit4 loss is not compensated by DLG1, which acts
upstream in the pathway and whose expression is stabilized after
the rise and fall of Ddit4 (Cotter et al., 2010). Interestingly, we
found that Dlg1 expression is normal in Ddit4-null nerves (data
not shown). On the other hand, in Dlg1-null nerves, mTORC1
activationmay induceDdit4 upregulation, resulting in a negative
feedback loop onmTOR activity and in normal myelin thickness
in adult nerves. Indeed, we found that, alongwithDdit4, HIF3 is
upregulated in Dlg1-null nerves at P20 (at both the mRNA and
protein level). It is known that mTORC1 activation may lead to
HIF1 expression, which in turn induces DDIT4 expression (El-
lisen, 2005; Schwarzer et al., 2005). Thus, by analogy, the tran-
sient AKT/mTORactivation inDlg1-null nervesmay induce both
HIF3 and DDIT4 expression downstream of mTORC1, thus
eliciting a negative feedback loop on mTOR activity.
The PI3K/AKT pathway and focal hypermyelination
In addition to the regulation of myelin thickness, the PI3K/AKT
pathway is believed to control localmyelin remodeling andmem-
brane homeostasis (Goebbels et al., 2010, 2012). Loss of either
DLG1 (Cotter et al., 2010) or PTEN (Goebbels et al., 2012) and
altered PI3K/AKT signaling at regions of noncompact myelin
leads to focal hypermyelination, defined as tomacula, recurrent
loops, and myelin outfoldings. Accordingly, focal hypermyelina-
tion in Pten-null mice is ameliorated by rapamycin, a known
mTORC1 inhibitor (Goebbels et al., 2012), with a greater effect
on tomacula than on myelin outfoldings. This latter observation
led to the hypothesis that myelin outfoldings represent a PIP3-
dependent phenomenon, whereas tomacula are linked to the
bulk of protein and lipid synthesis that is dependent onmTORC1
activation. This hypothesis is further supported by the fact that
loss of either the MTMR2 phospholipid phosphatase (Bolino et
al., 2000, 2004) or the guanosine nucleotide exchange factor for
cdc42, FGD4 (Stendel et al., 2007; Horn et al., 2012), which binds
to phospholipids, provokes demyelinating neuropathies with
myelin outfoldings.
Interestingly, inDdit4-null nerves we did not observe signs of
focal hypermyelination despite mTORC1 activation and in-
creased myelin thickness. The fact that Ddit4-null nerves do not
display myelin outfoldings might consistent with the hypothesis
thatmyelin outfolding formationmight depend onPIP3, which is
generated upstream of TSC1/2, the target of DDIT4. Further, the
fact that we did not observe any tomacula in Ddit4-null nerves
may suggest that tomacula are dependent on direct AKT activa-
tion rather than mTORC1. In this line, in Pten-null nerves rapa-
mycin treatment may rescue tomacula because it decreases AKT
phosphorylation (473) via the positive feedback between
mTORC1, mTORC2, and AKT (Goebbels et al., 2012). Indeed,
Pten-nullmouse nerves treatedwith rapamycin display decreased
levels of AKT phosphorylation at S473 compared with knockout
animals treated with vehicle (Goebbels et al., 2012).
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